Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Lung Neoplasms 3Ovarian Neoplasms 2Neoplasms 2Neoplasm, Residual 2NSCLC 2Leukemia, Myeloid, Chronic-Phase 2Kidney Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Philadelphia Chromosome 1Neoplasms, Second Primary 1Neoplasms by Site 1Lung Diseases 1Liver Neoplasms 1Leukemia, Biphenotypic, Acute 1Leukemia 1Gastro Intestinal Stromal Tumor 1Endometrial Neoplasms 1Congenital Abnormalities 1

Interventions

Pemetrexed 9Drug Therapy 9osimertinib 7Radiotherapy 6Carboplatin 6anlotinib 5Radiosurgery 5aflutinib 4Gefitinib 4Docetaxel 4Cisplatin 4tislelizumab 3pembrolizumab 3icotinib 3Vinorelbine 3Paclitaxel 3Gemcitabine 3Erlotinib Hydrochloride 3toripalimab 2dacomitinib 2camrelizumab 2apatinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2Liquid Biopsy 2Immune Checkpoint Inhibitors 2Chemotherapy, Adjuvant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × NSCLC × Tyrosine Kinase Inhibitors × Clear all
NCT04318938 2026-03-02

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Active not recruiting
118 enrolled
Thoracic

NSCLC

NCT03256981 2023-12-26

HALT

Institute of Cancer Research, United Kingdom

Phase 2/3 Unknown
113 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡